182 related articles for article (PubMed ID: 19331801)
1. Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in combined dyslipidemia.
Derosa G; Maffioli P; D'Angelo A; Salvadeo SA; Ferrari I; Fogari E; Gravina A; Mereu R; Palumbo I; Randazzo S; Cicero AF
Clin Invest Med; 2009 Apr; 32(2):E124-32. PubMed ID: 19331801
[TBL] [Abstract][Full Text] [Related]
2. Comparison between metalloproteinases-2 and -9 in healthy subjects, diabetics, and subjects with acute coronary syndrome.
Derosa G; D'Angelo A; Scalise F; Avanzini MA; Tinelli C; Peros E; Fogari E; Cicero AF
Heart Vessels; 2007 Nov; 22(6):361-70. PubMed ID: 18043992
[TBL] [Abstract][Full Text] [Related]
3. Metalloproteinase-2 and -9 in diabetic and nondiabetic subjects during acute coronary syndromes.
Derosa G; Cicero AF; Scalise F; Avanzini MA; Tinelli C; Piccinni MN; Peros E; Geroldi D; Fogari E; D'Angelo A
Endothelium; 2007; 14(1):45-51. PubMed ID: 17364896
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in diabetic and healthy subjects.
Derosa G; D'Angelo A; Tinelli C; Devangelio E; Consoli A; Miccoli R; Penno G; Del Prato S; Paniga S; Cicero AF
Diabetes Metab; 2007 Apr; 33(2):129-34. PubMed ID: 17320450
[TBL] [Abstract][Full Text] [Related]
5. Matrix metalloproteinase-2 and -9 levels in obese patients.
Derosa G; Ferrari I; D'Angelo A; Tinelli C; Salvadeo SA; Ciccarelli L; Piccinni MN; Gravina A; Ramondetti F; Maffioli P; Cicero AF
Endothelium; 2008; 15(4):219-24. PubMed ID: 18663625
[TBL] [Abstract][Full Text] [Related]
6. Matrix metalloproteinases 2 and 9 and their tissue inhibitors 1 and 2 in premenopausal obese women: relationship to cardiac function.
Kosmala W; Plaksej R; Przewlocka-Kosmala M; Kuliczkowska-Plaksej J; Bednarek-Tupikowska G; Mazurek W
Int J Obes (Lond); 2008 May; 32(5):763-71. PubMed ID: 18197181
[TBL] [Abstract][Full Text] [Related]
7. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Matrix Metalloproteinase-2 (MMP-2) and -9 (MMP-9) and Their Tissue Inhibitors (TIMP-1 and TIMP-2) in Plasma from Patients with Neurodegenerative Dementia.
Tuna G; Yener GG; Oktay G; İşlekel GH; Kİrkalİ FG
J Alzheimers Dis; 2018; 66(3):1265-1273. PubMed ID: 30412498
[TBL] [Abstract][Full Text] [Related]
9. [Metalloproteinases MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 levels in children and adolescents with type 1 diabetes].
Florys B; Głowińska B; Urban M; Peczyńska J
Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2006; 12(3):184-9. PubMed ID: 17020653
[TBL] [Abstract][Full Text] [Related]
10. Matrix metalloproteinase-2, -9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension.
Derosa G; D'Angelo A; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo S; Montagna L; Gravina A; Ferrari I; Galli S; Paniga S; Tinelli C; Cicero AF
Endothelium; 2006; 13(3):227-31. PubMed ID: 16840178
[TBL] [Abstract][Full Text] [Related]
11. Serum levels of matrix metalloproteinases MMP-2 and MMP-9 and their inhibitors in women with glucose intolerance in pregnancy and normal controls.
Stojanovic N; Lewandowski K; Salata I; Bienkiewicz M; Tuck S; Prelevic G; Press M
Gynecol Endocrinol; 2010 Mar; 26(3):201-7. PubMed ID: 19526397
[TBL] [Abstract][Full Text] [Related]
12. Gelatinase A (MM-2), gelatinase B (MMP-9) and their inhibitors (TIMP 1, TIMP-2) in serum of women with endometriosis: Significant correlation between MMP-2, MMP-9 and their inhibitors without difference in levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in relation to the severity of endometriosis.
Salata IM; Stojanovic N; Cajdler-Łuba A; Lewandowski KC; Lewiński A
Gynecol Endocrinol; 2008 Jun; 24(6):326-30. PubMed ID: 18584412
[TBL] [Abstract][Full Text] [Related]
13. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer.
Oberg A; Höyhtyä M; Tavelin B; Stenling R; Lindmark G
Anticancer Res; 2000; 20(2B):1085-91. PubMed ID: 10810401
[TBL] [Abstract][Full Text] [Related]
14. Plasma matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-2, and CD40 ligand levels in patients with stable coronary artery disease.
Tayebjee MH; Lip GY; Tan KT; Patel JV; Hughes EA; MacFadyen RJ
Am J Cardiol; 2005 Aug; 96(3):339-45. PubMed ID: 16054454
[TBL] [Abstract][Full Text] [Related]
15. Imbalanced matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 activities in patients with thromboangiitis obliterans.
Dellalibera-Joviliano R; Jacob-Ferreira AL; Joviliano EE; Tanus-Santos JE; Evora PR
Vasc Med; 2012 Apr; 17(2):73-8. PubMed ID: 22402936
[TBL] [Abstract][Full Text] [Related]
16. Gelatinases and their tissue inhibitors in a group of subjects with metabolic syndrome.
Hopps E; Lo Presti R; Montana M; Noto D; Averna MR; Caimi G
J Investig Med; 2013 Aug; 61(6):978-83. PubMed ID: 23661104
[TBL] [Abstract][Full Text] [Related]
17. Plasma MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 during human orthotopic liver transplantation. The effect of aprotinin and the relation to ischemia/reperfusion injury.
Kuyvenhoven JP; Molenaar IQ; Verspaget HW; Veldman MG; Palareti G; Legnani C; Moolenburgh SE; Terpstra OT; Lamers CB; van Hoek B; Porte RJ
Thromb Haemost; 2004 Mar; 91(3):506-13. PubMed ID: 14983226
[TBL] [Abstract][Full Text] [Related]
18. Effects of n-3 PUFAs on postprandial variation of metalloproteinases, and inflammatory and insulin resistance parameters in dyslipidemic patients: evaluation with euglycemic clamp and oral fat load.
Derosa G; Cicero AF; Fogari E; D'Angelo A; Bonaventura A; Romano D; Maffioli P
J Clin Lipidol; 2012; 6(6):553-64. PubMed ID: 23312051
[TBL] [Abstract][Full Text] [Related]
19. Alterations in peripheral blood levels of TIMP-1, MMP-2, and MMP-9 in patients with type-2 diabetes.
Lee SW; Song KE; Shin DS; Ahn SM; Ha ES; Kim DJ; Nam MS; Lee KW
Diabetes Res Clin Pract; 2005 Aug; 69(2):175-9. PubMed ID: 16005367
[TBL] [Abstract][Full Text] [Related]
20. Elevated plasma levels of TIMP-1 correlate with plasma suPAR/uPA in patients with chronic myeloproliferative disorders.
Jensen MK; Holten-Andersen MN; Riisbro R; de Nully Brown P; Larsen MB; Kjeldsen L; Heickendorff L; Brünner N; Hasselbalch HC
Eur J Haematol; 2003 Nov; 71(5):377-84. PubMed ID: 14667201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
